fluvoxamine

Fluvoxamine is an oral **small-molecule selective serotonin reuptake inhibitor** antidepressant primarily developed by Solvay and marketed for psychiatric disorders including **obsessive-compulsive disorder** and **major depressive disorder** in many markets; in the United States, the immediate-release and controlled-release Luvox products have been marketed by Jazz Pharmaceuticals, and authorized generic fluvoxamine maleate rights were licensed to ANI Pharmaceuticals. Its main pharmacology is potent inhibition of the **serotonin transporter**, increasing serotonergic neurotransmission. Fluvoxamine is also widely described as a **sigma-1 receptor agonist**, a property explored in neuropsychiatric and repurposing settings. Beyond approved psychiatric uses, the provided literature describes investigator-driven or exploratory development in schizophrenia symptom domains, alcohol dependence with comorbid depression, hyperkinetic movement disorders, and preclinical anti-inflammatory repurposing work in chronic obstructive pulmonary disease.

Brand names

LuvoxLuvox CRFaverinDumyroxFloxyfral

Other names

fluvoxamine maleate氟伏沙明